vs
Side-by-side financial comparison of Align Technology (ALGN) and SINOVAC BIOTECH LTD (SVA). Click either name above to swap in a different company.
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandib...
Sinovac Biotech Ltd. is a Chinese biopharmaceutical company based in Haidian District, Beijing that focuses on the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. The company was listed on the Nasdaq but the exchange halted Sinovac's trading in February 2019 due to a proxy fight. The company has faced bribery probes in China. Its COVID-19 vaccine was the target of a covert disinformation campaign by the US government and a ...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $995.7M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $979.3M | — | ||
| Q4 24 | $995.2M | — | ||
| Q3 24 | $977.9M | — | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $997.4M | — |
| Q4 25 | $135.8M | — | ||
| Q3 25 | $56.8M | — | ||
| Q2 25 | $124.6M | — | ||
| Q1 25 | $93.2M | — | ||
| Q4 24 | $103.8M | — | ||
| Q3 24 | $116.0M | — | ||
| Q2 24 | $96.6M | — | ||
| Q1 24 | $105.0M | — |
| Q4 25 | 65.3% | — | ||
| Q3 25 | 64.2% | — | ||
| Q2 25 | 69.9% | — | ||
| Q1 25 | 69.5% | — | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.7% | — | ||
| Q2 24 | 70.3% | — | ||
| Q1 24 | 70.0% | — |
| Q4 25 | 14.8% | — | ||
| Q3 25 | 9.7% | — | ||
| Q2 25 | 16.1% | — | ||
| Q1 25 | 13.4% | — | ||
| Q4 24 | 14.5% | — | ||
| Q3 24 | 16.6% | — | ||
| Q2 24 | 14.3% | — | ||
| Q1 24 | 15.5% | — |
| Q4 25 | 13.0% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 9.5% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 11.9% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.5% | — |
| Q4 25 | $1.88 | — | ||
| Q3 25 | $0.78 | — | ||
| Q2 25 | $1.72 | — | ||
| Q1 25 | $1.27 | — | ||
| Q4 24 | $1.40 | — | ||
| Q3 24 | $1.55 | — | ||
| Q2 24 | $1.28 | — | ||
| Q1 24 | $1.39 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
